NxStage(R) Announces New Vice President and General Manager, International
LAWRENCE, Mass., Jan 19, 2010 /PRNewswire via COMTEX/ — NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that John Mullen has joined the Company as Vice President and General Manager, International. This newly created position will manage NxStage’s international growth initiatives.
Opportunities to leverage our success and leadership with NxStage technology within certain international regions are great and timely, particularly in home hemodialysis, said Jeff Burbank, President and CEO of NxStage Medical. Creating this position underscores our commitment to broaden access to our therapy and achieve positive cash flow in the near term. John Mullen’s extensive background in international development for medical device companies will be a tremendous asset to our team as we advance these initiatives.
Mullen brings to NxStage over 15 years of experience building international businesses in the medical industry. Most recently, Mullen held the position of Global VP, Sales & Marketing, for Cayenne Medical, a company focused on establishing new arthroscopic surgery innovations. Prior to that, Mullen held a variety of market development and general management positions with Smith & Nephew, both in the U.S. and Europe. Based at the Company’s corporate headquarters in Lawrence, Mass., Mullen will be primarily responsible for developing and managing international business and will report directly to Joseph Turk, Senior Vice President of Commercial Operations.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. For more information on NxStage and its products, please visit NxStage’s website at https://www.nxstage.com/.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage’s filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2009. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact
————————–
Kristen Sheppard
NxStage Medical, Inc.
ir@nxstage.com
978-332-5923
Media Contact
————-
Jim Weinrebe
Schwartz Communications, Inc.
nxstage@schwartz-pr.com
781-684-0770
SOURCE NxStage Medical, Inc.
